Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 13/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333533 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL11548502 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL1532533 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL17070856 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL1845901 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL1843245 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL10464105 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL11020473 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL4107182 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL4107178 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161182-A1 | ANTIMICROBIAL COMPOSITIONS | BIO-ACTIVES SYNERGIO LTD (IL) | 2025-05-22 | — | — | US | claimed |
| EP-4469037-A1 | ANTIMICROBIAL COMPOSITIONS | Bio-Actives Synergio Ltd (IL) | 2024-12-04 | — | — | EP | claimed |
| WO-2023144808-A1 | ANTIMICROBIAL COMPOSITIONS | BIO-ACTIVES SYNERGIO LTD (IL) | 2023-08-03 | — | — | WO | claimed |
| US-20250161182-A1 | ANTIMICROBIAL COMPOSITIONS | BIO-ACTIVES SYNERGIO LTD (IL) | 2025-05-22 | — | — | US | disclosed |
| EP-4469037-A1 | ANTIMICROBIAL COMPOSITIONS | Bio-Actives Synergio Ltd (IL) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144808-A1 | ANTIMICROBIAL COMPOSITIONS | BIO-ACTIVES SYNERGIO LTD (IL) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161182-A1 | ANTIMICROBIAL COMPOSITIONS | NOD2, PYCARD, CLPP | SMN1; SMN2 4274/4885LMNA 2204/4885KMT2A 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.